Kayfanda
odevixibat · Ipsen Pharma
EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Kayfanda is used for
Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Kayfanda
- Active substance
- odevixibat
- Disease area
- Pruritus; Alagille Syndrome
- Medicine group
- Bile and liver therapy
- ATC code
- A05AX05
- Marketing authorisation holder
- Ipsen Pharma
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kayfanda used for?
Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1).
What is the active substance in Kayfanda?
Kayfanda contains odevixibat.
Who makes Kayfanda?
The EU marketing authorisation holder is Ipsen Pharma.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU